FDA 483 - Merck & Company - January 20, 2021

An FDA inspection of Merck & Company in Rahway, NJ, identified a failure to ensure proper monitoring of a clinical study. Specifically, the firm did not submit monitoring follow-up letters with visit reports within the required timeframe as stipulated in their own Clinical Monitoring Plan. This indicates a procedural lapse in clinical trial oversight.